SEC Form 4 · accession 0001179110-19-002362
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas Donoghoe
Officer — SVP, Enterprise Innovation
Period of report
Feb 21, 2019
Accepted (ET)
Feb 22, 2019 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $79.02 | Feb 21, 2019 | A | 32,710 | A | Feb 21, 2020 | Feb 20, 2029 | Common Stock | 32,710 | 32,710 | D |
Explanation of responses
- F1Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,904 on February 21, 2020, 10,903 on February 21, 2021, and 10,903 on February 21, 2022.